Stock INDV INDIVIOR PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Indivior PLC Nasdaq

Equities

INDV

GB00BN4HT335

Real-time Estimate Cboe BZX
Other stock markets
 12:15:51 2024-06-03 EDT 		5-day change 1st Jan Change
18.34 USD +0.08% Intraday chart for Indivior PLC -0.92% +19.91%
05-23 Indivior Confirms FY24 Outlook MT
05-23 Transcript : Indivior PLC - Shareholder/Analyst Call

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
INDIVIOR PLC Stock Indivior PLC
+19.91% 2.48B -
MERCK KGAA Stock Merck KGaA
+16.20% 78.51B
A
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+13.10% 9B
A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+42.06% 4.96B -
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-14.54% 4.84B
A-
YUHAN CORPORATION Stock Yuhan Corporation
+9.01% 3.72B
B-
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-27.22% 2.19B
C-
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+15.83% 2.12B - -
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-39.50% 1.94B -
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. INDV Stock
  4. INDV Stock
  5. Ratings Indivior PLC